Want to create an interactive transcript for this episode?
Podcast: Surfing the MASH Tsunami
Episode: S3-E25.1 - NASH Drug Development in 2022: Late-Stage NASH Drugs and Their Path to Market
Description: This conversation is part of a broader overview of NASH drug development in 2022, led by Stephen Harrison and Jörn Schattenberg.Stephen starts this conversation by noting that the mechanics of the drug development pathway, which we discussed earlier this year in the context of NASH-TAG and strategies on how to shift away from traditional metrics, remain what they have been: same conditional endpoints (fibrosis improvement without worsening NASH or NASH resolution without worsening fibrosis, or improving both) and the same need for biopsy read as is has been. In this context, Stephen explains the difference between d...